Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide, Anti-PD-1 Antibody and Pegaspargase vs DDGP in Newly Diagnosed Stage III-IV NKTCL
NCT06255795Phase 3Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tucidinostat in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Ruijin Hospital. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT06255795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06255795.